AstraZeneca Paying Up To $2 Billion For Experimental Obesity Pill

AstraZeneca has agreed to pay up to $2 billion for an experimental pill used to treat obesity and type 2 diabetes—the latest pharmaceutical firm to bet on treatment similar to popular weight-loss and diabetes drugs Ozempic and Wegovy. AstraZeneca said Thursday it had reached an exclusive license…#astrazeneca #ecc5004 #glp1 #pascalsoriot #ozempic #wegovyormounjaro #novonordisk #wegovyandozempic #novonordisks #fda
Source: Reuters: Health - Category: Consumer Health News Source Type: news